Purple Biotech
PPBT
19 hedge funds and large institutions have $1.77M invested in Purple Biotech in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 4 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
0.05% more ownership
Funds ownership: 9.88% → 9.93% (+0.05%)
0% more funds holding
Funds holding: 19 → 19 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
7% less capital invested
Capital invested by funds: $1.9M → $1.77M (-$131K)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$167K |
| 2 |
Morgan Stanley
New York
|
+$35.9K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$33.1K |
| 4 |
Millennium Management
New York
|
+$15.3K |
| 5 |
VF
Virtu Financial
New York
|
+$11.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
WuXi AppTec
Shanghai,
China
|
-$151K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
-$3K |
| 3 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
-$1.56K |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$717 |
| 5 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$430 |
PPBT Hedge Fund Activity: Q1 2024 in Review
19 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Purple Biotech (PPBT) for Q1 2024, worth a combined $1.77M — down 6.9% from $1.9M a quarter earlier.
Fund positioning in PPBT was balanced in Q1 2024: 4 funds opened new positions, 4 closed out, 6 added to existing stakes and 2 trimmed.
The largest buyer was Armistice Capital, adding an estimated $167K. The largest seller was WuXi AppTec, exiting entirely with an estimated $151K sold.
- 19 institutional investors held Purple Biotech (PPBT) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $1.77M of Purple Biotech stock for Q1 2024, down 6.9% quarter-over-quarter.
- 4 funds opened new Purple Biotech positions in Q1 2024 and 4 closed out, a net change of 0 holders.
- The largest Purple Biotech buyer in Q1 2024 was Armistice Capital, an estimated $167K added.
- The largest Purple Biotech seller in Q1 2024 was WuXi AppTec, an estimated $151K sold.
Based on aggregated 13F filings for Q1 2024.